TrialDrug design, development and therapy2025
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects.
Yun Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.